Cadila Pharma shuts operations at Ahmedabad plant after employees test Covid-19 positive

By: |
Published: May 9, 2020 2:01 AM

The company manufactures 38 APIs and intermediates across various therapeutic categories — respiratory, diabetology, gastroenterology, pain management, orthopedics, etc. The company has more than 850 formulation products.

The statement further said that Cadila Pharmaceuticals has been at the forefront of producing high-quality affordable medicine. (Representative image)The statement further said that Cadila Pharmaceuticals has been at the forefront of producing high-quality affordable medicine.
(Representative image)

One of the largest privately held pharmaceutical companies in India, Gujarat-based Cadila Pharmaceuticals (CPL), has decided to shut its Ahmedabad plant’s operations from Friday after its 26 employees tested Covid-19 positive.

“Recently, 26 of our employees from our Dholka manufacturing facility tested positive for Covid-19. Following this, we have closed our operations on our own. Now we are undertaking deep sanitization of the plant and its surroundings. We are cooperating with the local administration at all levels to ensure the safety and security of our facility and surroundings,” said the company in its official statement, adding that the management is taking this opportunity to reiterate that the safety, health and well-being of the company’s employees are of paramount importance.

The statement further said that Cadila Pharmaceuticals has been at the forefront of producing high-quality affordable medicine.

“Being an essential industry, we remain committed to restore normalcy at the plant in consultation with authorities at the earliest with commitment to adhere all precautions,” said the company.

The six-decade-old company headed by Rajiv Modi is one of the leading active pharmaceuticals ingredient (API) manufacturing companies in the country. It is considered one of the few companies in the country which is vertically integrated with a very strong positioning in both the API and the formulations markets.

Cadila Pharmaceuticals exports its products to more than 90 countries across the globe. The company manufactures 38 APIs and intermediates across various therapeutic categories — respiratory, diabetology, gastroenterology, pain management, orthopedics, etc. The company has more than 850 formulation products.

CPL has its own contract research operation at its Dholka facility, situated on the outskirts of Ahmedabad. The unit manages contract research activities ranging from pre-clinical, BA-BE to Phase II to Phase IV trials.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Preventing Monopoly: Centre decides to put caps on cross-holding by telcos and OTTs
2Samsung pips Vivo to regain number two position in smartphone sales in India
3Let’s get phygital, say retailers as Covid revolutionises shopping